108 patents currently held
54 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Mar 2027. from the record
Of the 54 now held by other companies, 6 name United States of America as Represented by the Secretary Department of Health and Human Services as their current owner, and 48 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
26
Ending by 2030
Mar 2027
Next term end
84
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2027 · High confidence
Also notable
Ends Mar 2033 · High confidence
Also notable
Ends Sep 2029 · Medium confidence
Nitrated Lipids and Methods of Making and Using Thereof
US 7,776,916
The most cited patent in this portfolio, cited by 83 later US patents, top 10% of utility patents granted in 2010 in our data. Protection runs to 2027.
Methods and Compositions for Alphavirus Replicons
US 8,961,995
Cited by 38 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
MSP Nanopores and Related Methods
US 9,170,230
The largest patent family in this portfolio, 11 related applications, renewed at every maintenance window due so far. Protection runs to 2029.
Formerly held, still cited
Notable
Ends Sep 2029 · Medium confidence
Cited by 70 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by University of Washington
Also notable
Ends Oct 2039 · High confidence
Cited by 9 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2039.
now held by Afl Telecommunications LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 26, 2026The maintenance fee for Nonhuman Mammal whose mtDNA is from a nonhuman mammal resistant to a selected disease or disorder and whose nDNA is from a nonhuman donor mammal more susceptible to the selected disease or disorder (US 9,040,771) comes due Nov 26, 2026. Unpaid by May 26, 2027, it lapses early.
- 2 fees due Jan 2 to 16, 2027 · next Jan 2
- 2 fees due Mar 12 to 29, 2027 · next Mar 12
- 3 fees due Apr 15 to 27, 2027 · next Apr 15
- 3 fees due May 7 to 17, 2027 · next May 7
- 2 fees due Jun 19 to 30, 2027 · next Jun 19
- 1 fee due Jul 2, 2027The maintenance fee for MSP Nanopores and Uses Thereof (US 11,858,966) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Protective Helmet Systems That Enable the Helmet to Rotate Independent of the Head (US 10,568,377) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 5 fees due Oct 2 to 14, 2027 · next Oct 2
Recent changes
- Nov 10Assignment recorded on 1 record: Bhatt, Surya Prakash and 2 others to The UAB Research Foundation Recorded Nov 10, 2026, executed Sep 18, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76705, frame 276.
- Nov 3Assignment recorded on 1 record: Saad, Ayman and 2 others to The UAB Research Foundation Recorded Nov 3, 2026, executed Apr 2, 2018. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76619, frame 662.
- 3 of the patents on this record were granted since Aug 17, 2026
- 2 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 84 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| MSP Nanopores and Related Methods | 8 in force | to Sep 2029 |
| MSP Nanopores and Uses Thereof | 4 in force | to May 2035 |
| Inhaled Respiratory Probiotics for Lung Diseases of Infancy, Childhood and Adulthood | 3 in force | to Aug 2038 |
| Method for Detecting an Open-Phase Condition of a Transformer | 3 in force | to Feb 2034 |
| Methods and Compositions Related to Soluble Monoclonal Variable Lymphocyte Receptors of Defined Antigen Specificity | 3 in force | to Jul 2027 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,634,685 | Pneumococcal Serotypes held by Fundacao Oswaldo Cruz In force · High confidence | In force | High confidence | |
| US 7,776,916 | Nitrated Lipids and Methods of Making and Using Thereof held by The UAB Research Foundation, University College Cardiff Consultants Limited and Morehouse School of Medicine, Inc. In force · High confidence | In force | High confidence | |
| US 7,868,139 | Composotions and Methods for the Identification and Treatment of Immune-Mediated Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 10,239,936 | Methods and Compositions Related to Soluble Monoclonal Variable Lymphocyte Receptors of Defined Antigen Specificity In force · High confidence | In force | High confidence | |
| US 10,870,692 | Methods and Compositions Related to Soluble Monoclonal Variable Lymphocyte Receptors of Defined Antigen Specificity In force · High confidence | In force | High confidence | |
| US 11,945,857 | Methods and Compositions Related to Soluble Monoclonal Variable Lymphocyte Receptors of Defined Antigen Specificity In force · High confidence | In force | High confidence | |
| US 12,788,242 | Photobleaching Method In force · High confidence | In force | High confidence | |
| US 7,734,344 | Methods, Systems and Computer Program Products to Inhibit Ventricular Fibrillation During Cardiopulmonary Resuscitation In force · High confidence | In force | High confidence | |
| US 8,153,443 | Characterization of the CBIR1 Antigenic Response for Diagnosis and Treatment of Crohn's Disease In force · High confidence | In force | High confidence | |
| US 8,039,588 | Variable Lymphocyte Receptors In force · High confidence | In force | High confidence |
Also on record, not counted in the 108: 54 patents in force now held by others · 145 patents ended · 99 applications pending · 199 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.